Security Snapshot

KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) Institutional Ownership

CUSIP: 483497103

13F Institutional Holders and Ownership History from Q4 2016 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

161

Shares (Excl. Options)

66,955,502

Price

$16.15

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
KALV on Nasdaq
Shares outstanding
51,679,622
Price per share
$20.12
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
66,955,502
Total reported value
$1,081,342,589
% of total 13F portfolios
0%
Share change
+6,300,347
Value change
+$110,817,400
Number of holders
161
Price from insider filings
$20.12
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 483497103.
  • 161 institutions reported positions in Q4 2025.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 161 to 83 between Q4 2025 and Q1 2026.
  • Reported value moved from $1,081,342,589 to $303,146,952.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 161 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 483497103?
CUSIP 483497103 identifies KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TANG CAPITAL MANAGEMENT LLC 9.9% $63,650,358 4,941,798 TANG CAPITAL MANAGEMENT, LLC 31 Mar 2025
Frazier Life Sciences Public Fund, L.P. 6.9% +42% $42,222,226 +$12,986,864 3,466,521 +44% Frazier Life Sciences Public Fund, L.P. 01 Nov 2025
Capital World Investors 6.4% $40,927,321 3,177,587 Capital World Investors 31 Mar 2025
Point72 Asset Management, L.P. 5.5% $44,930,777 2,781,902 Point72 Asset Management, L.P. 05 Jan 2026
MILLENNIUM MANAGEMENT LLC 3.7% -37% $38,472,378 -$21,157,246 1,912,146 -35% Millennium Management LLC 31 Mar 2026
Vestal Point Capital, LP 1.5% $9,135,000 750,000 Vestal Point Capital, LP 30 Sep 2025

As of 31 Dec 2025, 161 institutional investors reported holding 66,955,502 shares of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV). This represents 130% of the company’s total 51,679,622 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) together control 109% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VR ADVISER, LLC 13% 6,728,985 0% 5.4% $108,673,108
Frazier Life Sciences Management, L.P. 9.8% 5,039,867 0% 2.2% $81,393,852
SUVRETTA CAPITAL MANAGEMENT, LLC 9.2% 4,768,712 0% 1.9% $77,014,699
TANG CAPITAL MANAGEMENT LLC 8.8% 4,573,530 -9.3% 3.6% $73,862,510
BlackRock, Inc. 7.3% 3,754,148 +20% 0% $60,629,492
MILLENNIUM MANAGEMENT LLC 5.6% 2,896,666 +38% 0.03% $46,781,156
Capital World Investors 5.4% 2,808,583 -12% 0.01% $45,358,615
VANGUARD GROUP INC 4.9% 2,509,020 +0.32% 0% $40,520,674
SILVERARC CAPITAL MANAGEMENT, LLC 4.7% 2,427,118 +78% 5.7% $39,197,956
Point72 Asset Management, L.P. 4.4% 2,283,766 0.06% $36,882,821
Woodline Partners LP 3.7% 1,921,092 +0.02% 0.12% $31,025,636
STATE STREET CORP 3.7% 1,911,691 +21% 0% $30,873,810
Vestal Point Capital, LP 3.7% 1,890,000 +152% 1.1% $30,523,500
Kynam Capital Management, LP 3.5% 1,810,954 +199% 1.9% $29,246,907
Parkman Healthcare Partners LLC 3.4% 1,768,508 +1.9% 2.7% $28,561,404
EMERALD ADVISERS, LLC 2.6% 1,340,495 -0.8% 0.67% $21,648,994
Octagon Capital Advisors LP 2.5% 1,273,333 0% 2.6% $20,564,328
SCHRODER INVESTMENT MANAGEMENT GROUP 2.3% 1,171,755 +1.1% 0.01% $18,923,843
GEODE CAPITAL MANAGEMENT, LLC 1.8% 944,077 +1.7% 0% $15,251,132
EMERALD MUTUAL FUND ADVISERS TRUST 1.7% 855,461 -6.8% 0.67% $13,815,695
GOLDMAN SACHS GROUP INC 1.6% 835,304 -54% 0% $13,490,160
Elmind Capital, LP 1.6% 801,300 0% 3.8% $12,940,995
ARMISTICE CAPITAL, LLC 1.5% 800,000 0.32% $12,920,000
BARCLAYS PLC 1.4% 700,573 +21% 0% $11,314,253
MORGAN STANLEY 1.4% 700,227 +24% 0% $11,308,665

Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 15,061,420 $303,146,952 +$14,022,117 $20.13 83
2025 Q4 66,955,502 $1,081,342,589 +$110,817,400 $16.15 161
2025 Q3 58,620,381 $714,026,876 +$51,785,657 $12.18 143
2025 Q2 54,445,883 $615,513,091 -$5,352,606 $11.30 138
2025 Q1 54,890,685 $633,782,153 +$5,364,849 $11.54 127
2024 Q4 55,190,249 $467,414,520 +$30,397,001 $8.47 129
2024 Q3 48,412,221 $560,958,769 +$549,019 $11.58 120
2024 Q2 48,235,227 $568,211,775 +$14,329,598 $11.78 118
2024 Q1 46,978,393 $557,162,578 +$117,921,974 $11.86 128
2023 Q4 36,983,052 $453,043,903 +$5,790,575 $12.25 92
2023 Q3 36,263,336 $349,220,877 +$17,912,528 $9.63 101
2023 Q2 34,451,516 $310,062,547 +$8,864,955 $9.00 93
2023 Q1 33,720,468 $265,039,035 -$7,240,065 $7.86 87
2022 Q4 33,810,837 $228,557,857 +$23,549,577 $6.76 88
2022 Q3 25,639,454 $372,024,783 +$16,611,056 $14.51 88
2022 Q2 24,252,971 $238,647,172 -$18,209,799 $9.84 84
2022 Q1 23,950,478 $353,046,504 -$11,733,222 $14.74 84
2021 Q4 23,784,064 $314,614,009 -$24,155,895 $13.23 93
2021 Q3 23,380,949 $408,241,803 -$21,548,932 $17.45 101
2021 Q2 24,320,398 $582,722,986 +$12,095,008 $23.96 108
2021 Q1 23,504,843 $603,806,496 +$241,335,972 $25.69 115
2020 Q4 14,665,664 $278,488,932 +$4,362,596 $18.99 79
2020 Q3 16,200,799 $203,913,450 +$2,818,589 $12.59 61
2020 Q2 15,986,858 $193,667,544 +$9,419,888 $12.10 72
2020 Q1 15,660,431 $119,795,221 +$17,243,054 $7.65 68
2019 Q4 13,721,637 $244,359,076 +$13,370,440 $17.81 73
2019 Q3 13,183,569 $152,927,098 -$33,989,311 $11.60 75
2019 Q2 14,786,402 $327,505,666 +$6,277,733 $22.15 74
2019 Q1 13,905,857 $397,892,000 +$23,850,655 $28.62 67
2018 Q4 12,995,790 $256,399,000 +$7,695,219 $19.75 56
2018 Q3 12,319,459 $272,385,000 +$112,676,598 $22.11 46
2018 Q2 6,316,266 $51,280,000 -$1,600,370 $8.12 24
2018 Q1 6,502,232 $61,590,000 +$133,882 $9.48 23
2017 Q4 6,484,043 $63,213,000 -$2,998,314 $9.75 23
2017 Q3 7,715,060 $52,230,000 +$2,314,839 $6.73 15
2017 Q2 7,368,527 $54,075,000 -$1,766,461 $7.36 17
2017 Q1 7,587,480 $59,162,000 +$2,023,038 $7.81 18
2016 Q4 7,331,083 $51,493,000 +$46,974,000 $7.07 18
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .